emd 521873
mAbexperimentalADC
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2006 (NCT01032681)
Timeline
Indications
Mechanism of action
- dsDNAImmunity, passive
dsDNA immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- IL2
Oral
No
Parenteral
No
Topical
No
Also known as
- emd 521873
- msb0010445
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01973608 | Phase 2 | Jan 1, 2014 | Merck KGaA, Merck Serono |
| NCT00879866 | Phase 1 | Apr 1, 2009 | Merck KGaA |
| NCT01032681 | Phase 1 | Dec 1, 2006 | Merck KGaA |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 3 | 2 | 2 | 2006 |
| Merck Serono | For profit | 1 | 1 | 1 | 2014 |
2 organizations
Page 1 / 1